ABSTRACT Severe combined immunodeficiency (SCID) is potentially correctable by bone marrow transplantation if a patient has a suitable histocompatible donor. In the absence of an HLA-matched donor, lethal graft-versus-host disease (GVHD), which is mediated by alloreactive donor T cells, may occur. In an attempt to prevent GVHD in one SCID patient lacking a matched donor, we treated maternal haplomismatched bone marrow with a unique nonmitogenic T-cell-specific monoclonal antibody (anti-T12) and complement to remove mature T cells. Despite the removal of >99% mature T cells, the child developed significant life-threatening GVHD, which was terminated by a 5-day course of intravenous anti-T12. Subsequently, immune reconstitution occurred by 6 wk: the mature circulating T cells proliferated in response to soluble and allo-antigens in vitro and provided help for B-cell immunoglobulin synthesis. The patient was removed from a protective environment and discharged without evidence of further infection. Both HLA and chromosomal analyses showed that the circulating cells in the patient were of maternal origin. More importantly, the maternal T cells were no longer reactive with recipient cells. Mixing experiments indicated that the state of tolerance that resulted in this chimera was not due to active suppression. We conclude that HLA-mismatched transplantation for SCID can be undertaken if mature alloreactive donor T lymphocytes are depleted before and after bone marrow grafting.
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Patients with severe combined immunodeficiency (SCID) have major defects in immune function because they generally lack both T and B lymphocytes (1) (2) (3) . Clinical manifestations of this defective immunity include early onset of life-threatening pulmonary infection, moniliasis, chronic diarrhea, and wasting that progressively worsens despite conservative therapies. Although the precise etiology ofSCID has not been determined, previous studies indicated that the circulating lymphoid cells of SCID patients are of two major phenotypes as defined by monoclonal antibody analysis: either TlO+T3-T4-T8-or TlO+T3+T4+T8+ (4) . The former population is derived from a percursor bone marrow or early thymocyte compartment whereas the latter represents a late stage of thymocyte differentiation (5) . Only those SCID patients with circulating cells of the more mature TlO+T3+T4+T8+ phenotype demonstrated immunologic function.
Corrective therapy for SCID currently requires bone marrow transplantation (6) . Unfortunately, the invariably lethal graft-versus-host disease (GVHD) accompanying transplantation with histoincompatible cells has necessitated donor recipient HLA identity as a prerequisite for transplantation. This has, in effect, denied potentially corrective therapy to the majority ofpatients (=60%). Moreover, even among the 40% ofindividuals who are transplanted with donor bone marrow cells matched at HLA-A, -B, and -DR loci, there is often some degree of GVHD or post-transplant infection or both.
Recent studies in animal model systems, however, suggest a strategy to circumvent these difficulties (7, 8) . In the mouse, for example, removal of immunocompetent T lymphocytes from donor marrow before transplantation allows successful haplotype-mismatched engraftment without GVHD. To explore the utility of this approach in the human, we used a monoclonal antibody to eliminate virtually all mature T cells from a haplotype-mismatched donor bone marrow innoculum before transplantation of a patient with SCID. The transient GVHD that followed was terminated by intravenous administration of the same antibody with reconstitution of mature T-and B-cell function by 6 wk after transplantation. The recipient is currently a stable chimera with circulating donor T lymphocytes that have become tolerant to recipient HLA antigens.
MATERIALS AND METHODS Production of Monoclonal Antibodies and Cell Sorter Analysis. A series of monoclonal antibodies was used to define cell surface antigens on human lymphocytes of T-and B-cell lineage isolated by density centrifugation (9) . The production and characterization of monoclonal antibodies anti-T3, anti-T4, anti-T8, anti-T6, anti-T10, anti-Tll, anti-Ia, and anti-Bl have been described (10) (11) (12) (13) (14) , and their specificities are further defined in Table 1 .
In addition, we used a T-cell-specific monoclonal antibody termed anti-T12, developed through a previously reported hybridization and screening strategy (5) . Although similar to anti-T3 in cellular expression (present on all peripheral T cells and mature medullary thymocytes and absent from cells of non-T lineage and immature thymocytes), it defines a unique cell surface glycoprotein of 120,000 daltons, in contrast to anti-T3, which defines a 19,000-dalton cell surface glycoprotein (15) . The anti-T12 antibody was chosen for its selective binding pattern on mature T cells and medullary thymocytes and lack of mitogenicity on Tlymphocytes. Anti-T12 was shown to be of the IgM isotype by virtue of its reactivity with a goat anti-mouse IgM antibody and lack of reactivity with a goat anti-mouse IgG antibody (Meloy Laboratories, Springfield, VA).
Abbreviations: MHC, major histocompatibility complex; SCID, severe combined immunodeficiency; GVHD, graft-versus-host disease; MLC, mixed lymphocyte culture.
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Preparation of Functional and Phenotypic Analyses of Lymphoid Cells. In vitro T-cell proliferative responses to mitogens and antigens and B-cell immunoglobulin production after pokeweed mitogen stimulation were determined as described (16, 17) . Epics V cell sorter analysis of lymphoid cells with monoclonal antibodies, indirect immunofluorescence and microcytotoxicity assays, and chromosome banding used standard techniques (10, 18, 19 (12) . The latter monoclonal antibody defines a sheep erythrocyte receptor-associated antigen (15) . In contrast, there was no reactivity with anti-T3, anti-T4, anti-T8, or anti-T12 (Table 1) . These findings suggest that all circulating lymphoid cells of T lineage were immature. Moreover, no B cells were detectable in peripheral blood with anti-Bi, which defines a B-cell-specific antigen present throughout B-cell ontogeny (14) . Expression Proc. Nad Acad. before and 4 hr after anti-T12 treatment is shown in Fig. 1 To determine whether the circulating blood and bone marrow population after transplantation were ofthe maternal donor genotype, HLA and erythrocyte typing and chromosomal banding studies were performed 5 wk after transplantation. As shown in Table 3 , the maternal peripheral blood HLA lymphocyte genotype was distinct from the patient's HLA genotype since the former expressed Aw3O, Bw22, and Dr5 and lacked Aw23, Bw44, and Dr4, whereas the converse was true for the latter. After transplantation, the patient's peripheral blood and bone marrow were of the maternal HLA genotype. Further support for this idea was the finding that karyotyping of the patient's lymphocytes after transplantation showed bright satellites on both chromosomes 22 by banding analysis that were identical to the mother's pattern (19) . Erythrocyte group analysis, likewise, demonstrated that erythroid cells were of maternal origin after transplantation.
Given the pretransplant in vitro data showing that the patient's lymphocytes were stimulatory for maternal T cells in a mixed lymphocyte culture (MLC) as well as the development of GVHD, it was important to determine whether or not the maternal T lymphocytes in the recipient after transplantation were reactive with original recipient cells obtained and cryopreserved before transplantation. As shown in Table 4 (Exp. 1), maternal lymphocytes taken from the mother proliferated in MLC against irradiated recipient bone marrow obtained before transplantation. In contrast, lymphocytes of maternal genotype present in the recipient after transplantation (Exp. 2) were no longer responsive to the same pretransplant bone marrow. These studies indicated that the maternal T lymphocytes circulating in the child were no longer reactive with the child's cells. To determine whether this inability to respond to recipient major histocompatibility complex (MHC) was secondary to suppression or tolerance, a mixing study was performed in which maternal lymphocytes were combined (1:1) with recipient lymphocytes of maternal genotype and added to the pretransplant irradiated cryopreserved bone marrow specimen from the recipient in a MLC (Exp. 3). As shown, with this mixture, significant proliferation was obtained. This degree ofproliferation represented slightly more than the average proliferation of experiments 1 and 2 and strongly argues against active suppression by maternal lymphocytes in the recipient as the major mechanism ofproliferation inhibition. Rather, it suggests that the circulating maternal lymphocytes had lost alloreactivity or become tolerant to recipient HLA antigens.
DISCUSSION
In the present study, we performed a bone marrow transplantation on a patient with SCID using maternal HLA-haplotype mismatched bone marrow that had been depleted of mature T lymphocytes. T lymphocytes were eliminated from the bone marrow before infusion by using anti-T12/rabbit complement. Three cycles of in vitro anti-T12/complement treatment reduced the percentage ofT cells in the innoculum by a factor of 0.001 as determined by indirect immunofluorescence. Further reduction of T cells in the donor marrow was not attempted because of the possible adverse effects in putative donor stem cells. Nevertheless, significant clinical GVHD, manifested by skin rash, hepatitis, diarrhea, and ascites, developed 10 days after transplantation. The patient was then treated by intrave- *HLA: Aw3O, 32; B14, Bw22; Dr3, 5. tHLA: Aw23, 32; B14, Bw44; Dr3, 4. nous infusion ofanti-T12, which resulted in termination ofsigns of GVHD. By 6 wk after transplantation, the patient was noted to have mature T and B lymphocytes in peripheral blood that were shown to respond normally to alloantigens in a MLC, the soluble antigen tetanus toxoid, and the mitogen phytohemagglutinin in vitro. In addition, her B lymphocytes were able to differentiate into plasma cells and secrete IgG in the presence of autologous T cells and pokeweed mitogen. Thus, it appears that normal immune reconstitution occurred in this child with SCID despite the use of haplotype-mismatched bone marrow. Currently, 8 months after discharge from the hospital, she continues to do well in growth, development, and psychomotor areas without any evidence of infection.
The hypothesis that T-cell depletion of donor bone marrow innoculum can prevent GVHD has been supported by work in several animal systems. In the mouse, anti-Thy 1/complement treatment of bone marrow before transplantation into irradiated H-2-incompatible hosts results in hematopoietic reconstitution and the absence of detectable GVHD (7) . Similarly, in the primate, agglutination of bone marrow cells with plant lectin can be used to differentially separate T-from non-T-lineage elements (8) . Bone marrow depleted of T lymphocytes in this fashion has been used to reconstitute haplotype-mismatched animals without GVHD. Although the removal of mature T lymphocytes was nearly complete in our patient, significant acute GVHD was observed. Since abrogation of GVHD followed the in vivo removal of T3+T12' T cells, the alloreactive lymphocytes responsible for GVHD were almost certainly derived from this residual maternal T-cell population, which expanded after transplantation. The presence of GVHD in our patient suggests that there was a greater histocompatibility difference in this parental into F1 transplant situation than in the murine and primate systems or that transient GVHD T-cell-specific monoclonal antibodies offer advantages over conventional antisera or lectin-depletion techniques (20, 21) . First, they can be tailored specifically to individual cell lineages and furthermore restricted to antigens expressed during either mature or immature stages of differentiation (5) . Second, they can be selected for various functional virtues, including the inability to activate the immune response or induce modulation ofsurface antigens that they define (20) . The latter is a necessary prerequisite to ensure successful complement-mediated lysis. Third, they can be derived from the appropriate immunoglobulin isotype to optimally fix complement and engage the reticuloendothelial system. In this regard, anti-T12 is a monoclonal antibody of the IgM isotype that fixes complement, detects a 120,000-dalton glycoprotein without initiating its modulation, does not induce lymphocyte proliferation or activation, and is restricted in its reactivity to mature immunocompetent T lymphocytes. Last, the quantity ofmonoclonal reagents is unlimited and, unlike heteroantisera, their specificity is constant.
It is clear that, after transplantation, all hematopoietic cells were of the maternal phenotype. Of note, transiently, there was the appearance of immature cells in the peripheral circulation. Nevertheless, after termination of GVHD, the subsequent mature T cells that appeared in the circulation did not mediate GVHD. These cells responded normally in a MLC, whereas, before transplantation, the child had no response. Despite this alloreactive capacity, the T lymphocytes ofmaternal HLA genotype did not react with the child's cryopreserved haplotypemismatched bone marrow. This state of tolerance within the chimera was not due to demonstrable suppressor cell mechanisms. Rather, mixing studies supported the hypothesis that cells that differentiated in the child had become tolerant to the child and were not immunosuppressed. These results are consistent with murine studies indicating that the development of recognition of "self MHC" is dependent not on the genotype of the T cell itself but rather on the MHC antigens expressed by thymic epithelial cells (22, 23) .
Previous studies indicated that patients with SCID had immature cells circulating in peripheral blood (4) . Whether this was due to the absence of normal precursor cells or the failure ofa microenvironment to facilitate differentiation was not clear.
The development of immunocompetent T lymphocytes after removal ofmature maternal T lymphocytes suggests that an intracellular defect rather than a microenvironmental defect is responsible for disease in our case.
The present study represents only one experience in haplotype-mismatched transplantation. In this regard, it is evident that a series of studies will be needed to determine the general applicability of such an approach to transplantation in situations in which HLA identical donors are lacking. However, the development of functional donor T lymphocytes that are tolerant to recipient HLA antigens in our patient and a successful HLA-A-, -B-mismatched transplant reported by others (24) suggest that, after initial mature donor T-cell depletion from bone marrow, HLA-mismatched transplantation is biologically rational and technically feasible. The potential for extending corrective bone marrow transplantation to individuals without previously suitable donors appears promising.
Note Added in Proof. Since the preparation ofthis manuscript, a second patient has been given a transplant in a similar fashion with paternal T lymphocyte-depleted HLA haplotype-mismatched bone marrow for Wiskott-Aldrich syndrome. At 3 wk after transplantation, hematologic reconstitution is evident.
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